| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| May 04, 2020 |
Director
Trans History: 11
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,923 | -- | 80,923 |
| May 04, 2020 |
Director
Trans History: 9
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 80,923 | -- | 80,923 |
| Feb 18, 2020 |
Chief Administrative Officer
Trans History: 6
|
Chief Administrative Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 100,000 | -- | 100,000 |
| Aug 23, 2018 |
Chief Scientific Officer
Trans History: 21
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 101,918 | -- | 110,503 |
| Aug 23, 2018 |
Chief Scientific Officer
Trans History: 21
|
Chief Scientific Officer | Form 4 | Conversion of derivative security | 104,167 | -- | -- |
| Feb 15, 2023 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 105,000 | -- | 231,373 |
| Sep 18, 2023 |
Chief Financial Officer
Trans History: 2
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 106,000 | -- | 106,000 |
| Mar 06, 2023 |
General Counsel
Trans History: 4
|
General Counsel | Form 3 | Initial Statement of Beneficial Ownership of Securities | 117,810 | -- | -- |
| Feb 15, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 120,000 | -- | 124,794 |
| Feb 15, 2023 |
Chief Operating Officer
Trans History: 19
|
Chief Operating Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 120,000 | -- | 339,338 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.